Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes

被引:5
作者
Konishi, Kentaro [1 ]
Tenmizu, Daisuke [1 ]
Takusagawa, Shin [2 ]
机构
[1] Astellas Pharma Inc, Drug Discovery Res, Anal & Pharmacokinet Res Labs, 21,Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan
[2] Astellas Pharma Inc, Dev, Clin Pharmacol, Chuo Ku, 2-5-1,Nihonbashi Honcho, Tokyo 1038411, Japan
关键词
UDP-GLUCURONOSYLTRANSFERASE; 2B7; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OVERACTIVE BLADDER; DOUBLE-BLIND; PHASE-III; LC-MS/MS; ALAMETHICIN; METABOLISM; INHIBITORS; EFFICACY;
D O I
10.1007/s13318-017-0450-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mirabegron is cleared by multiple mechanisms, including drug-metabolizing enzymes. One of the most important clearance pathways is direct glucuronidation. In humans, M11 (O-glucuronide), M13 (carbamoyl-glucuronide), and M14 (N-glucuronide) have been identified, of which M11 is one of the major metabolites in human plasma. The objective of this study was to identify the uridine 5'-diphosphate (UDP)-glucuronosyltransferase (UGT) isoform responsible for the direct glucuronidation of mirabegron using human liver microsomes (HLMs) and recombinant human UGTs (rhUGTs). Reaction mixtures contained 1-1000 mu M mirabegron, 8 mM MgCl2, alamethicin (25 mu g/mL), 50 mM Tris-HCl buffer (pH 7.5), human liver microsome (HLM) or rhUGT (1.0 mg protein/mL), and 2 mM UDP-glucuronic acid in a total volume of 200 mu L for 120 min at 37 A degrees C. HLMs from 16 individuals were used for the correlation study, and mefenamic acid and propofol were used for the inhibition study. Regarding M11 formation, rhUGT2B7 showed high activity among the rhUGTs tested (11.3 pmol/min/mg protein). This result was supported by the correlation between M11 formation activity and UGT2B7 marker enzyme activity (3-glucuronidation of morphine, r (2) = 0.330, p = 0.020) in individual HLMs; inhibition by mefenamic acid in pooled HLMs (IC50 = 22.8 mu M); and relatively similar K (m) values between pooled HLMs and rhUGT2B7 (1260 vs. 486 mu M). Regarding M13 and M14 formation, rhUGT1A3 and rhUGT1A8 showed high activity among the rhUGTs tested, respectively. UGT2B7 is the main catalyst of M11 formation in HLMs. Regarding M13 and M14 formation, UGT1A3 and UGT1A8 are strong candidates for glucuronidation, respectively.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 26 条
[1]   Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance [J].
Bhasker, CR ;
McKinnon, W ;
Stone, A ;
Lo, ACT ;
Kubota, T ;
Ishizaki, T ;
Miners, JO .
PHARMACOGENETICS, 2000, 10 (08) :679-685
[2]  
Coffman BL, 1997, DRUG METAB DISPOS, V25, P1
[3]   Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues [J].
Court, Michael H. ;
Zhang, Xiuling ;
Ding, Xinxin ;
Yee, Karen K. ;
Hesse, Leah M. ;
Finel, Moshe .
XENOBIOTICA, 2012, 42 (03) :266-277
[4]   Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder [J].
Eltink, Charlotte ;
Lee, Jennifer ;
Schaddelee, Marloes ;
Zhang, Wenhui ;
Kerbusch, Virginie ;
Meijer, John ;
van Marle, Sjoerd ;
Grunenberg, Nicole ;
Kowalski, Donna ;
Drogendijk, Ted ;
Moy, Selina ;
Iitsuka, Hiromi ;
van Gelderen, Marcel ;
Matsushima, Hiroshi ;
Sawamoto, Taiji .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (11) :838-849
[5]  
Fisher MB, 2000, DRUG METAB DISPOS, V28, P560
[6]   Quantification of Human Uridine-Diphosphate Glucuronosyl Transferase 1A Isoforms in Liver, Intestine, and Kidney Using Nanobore Liquid Chromatography-Tandem Mass Spectrometry [J].
Harbourt, David E. ;
Fallon, John K. ;
Ito, Shinya ;
Baba, Takashi ;
Ritter, Joseph K. ;
Glish, Gary L. ;
Smith, Philip C. .
ANALYTICAL CHEMISTRY, 2012, 84 (01) :98-105
[7]   A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder [J].
Herschorn, Sender ;
Barkin, Jack ;
Castro-Diaz, David ;
Frankel, Jeffrey M. ;
Espuna-Pons, Montserrat ;
Gousse, Angelo E. ;
Stoelzel, Matthias ;
Martin, Nancy ;
Gunther, Adrie ;
Van Kerrebroeck, Philip .
UROLOGY, 2013, 82 (02) :313-320
[8]  
Houston JB, 2000, DRUG METAB DISPOS, V28, P246
[9]   Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS [J].
Joo, Jeongmin ;
Kim, Yang-Weon ;
Wu, Zhexue ;
Shin, Jung-Hoon ;
Lee, Boram ;
Shon, Jong Cheol ;
Lee, Eun Young ;
Nguyen Minh Phuc ;
Liu, Kwang-Hyeon .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (04) :258-264
[10]   Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial [J].
Khullar, Vik ;
Amarenco, Gerard ;
Angulo, Javier C. ;
Cambronero, Javier ;
Hoye, Kjetil ;
Milsom, Ian ;
Radziszewski, Piotr ;
Rechberger, Tomasz ;
Boerrigter, Peter ;
Drogendijk, Ted ;
Wooning, Marianne ;
Chapple, Christopher .
EUROPEAN UROLOGY, 2013, 63 (02) :283-295